ஹார்வர்ட் இணைந்த ப்ரிகாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Syndicated Content (Refiles to add Reuters joint participation in event) By Julie Steenhuysen and Deena Beasley (Reuters) -A federal probe of the U.S. Food and Drug Administration’s approval of a controversial new Alzheimer’s disease drug should look into why that decision was made without clear evidence of patient benefit, a former adviser to the agency said on Tuesday. Acting FDA Commissioner Janet Woodcock earlier this month asked the Office of the Inspector General at the Department of Health and Human Services to investigate whether FDA representatives’ interactions with drugmaker Biogen Inc were inconsistent with agency policies.

United statesLos angelesAaron kesselheimJanet woodcockDeena beasleyJulie steenhuysenDepartment of healthHuman servicesOffice of the inspectorDrug administrationBiogen incInspector generalHarvard affiliated brighamPublic healthBill berkrotஒன்றுபட்டது மாநிலங்களில்